Search by Title Article Topic - Any -AdvocacyCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA Annual Scientific MeetingHFSA AwardsHFSA Board Certification ReviewHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterHFSA MembershipIn The NewsIndustryJournal of Cardiac FailureMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Feb 7 2022 | Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Industry News Industry Read More Jan 24 2022 | Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis Industry News Industry Read More Dec 10 2021 | EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Industry News Industry Read More Nov 22 2021 | Bristol Myers Squibb Announces New PDUFA Date for Mavacamten Industry News In The News Industry Read More Nov 16 2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Industry News Industry Read More Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Feb 7 2022 | Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Industry News Industry Read More
Jan 24 2022 | Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis Industry News Industry Read More
Dec 10 2021 | EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 Industry News Industry Read More
Nov 22 2021 | Bristol Myers Squibb Announces New PDUFA Date for Mavacamten Industry News In The News Industry Read More
Nov 16 2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction Industry News Industry Read More